Unicycive Therapeutics In... (UNCY)
NASDAQ: UNCY
· Real-Time Price · USD
4.71
0.08 (1.73%)
At close: Aug 15, 2025, 3:59 PM
4.72
0.32%
After-hours: Aug 15, 2025, 07:57 PM EDT
Unicycive Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | -271K | n/a | n/a | 675K | n/a | 951K | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 134K | n/a | n/a | 284K | 82K | 79K | 78K | 45K | 2K | 1K | 2K | 2K | 1K | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | -284K | -353K | -79K | -78K | 630K | -2K | 950K | -2K | -2K | -1K | n/a | n/a | n/a |
Operating Income | -7.99M | -9.26M | -6.25M | -7.4M | -9.2M | -6.31M | -5.94M | -4.32M | -4.2M | -5.33M | -5.55M | -3.64M | -3.54M | -2.75M | -4.71M | -779K | -731K |
Interest Income | 226K | 314K | 416K | 462K | 69K | 140K | 227K | 234K | 14K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | 570K | -21.52M | -4.1M | 9.86M | -20.96M | -7.8M | -4.41M | -3.84M | -14.57M | -5.33M | -5.56M | -3.64M | -3.54M | -2.75M | -5.2M | -1.1M | -964K |
Net Income | 570K | -21.52M | -4.1M | 9.86M | -20.96M | -7.8M | -4.41M | -3.84M | -25.15M | -5.33M | -5.56M | -3.64M | -3.54M | -2.75M | -5.2M | -1.1M | -964K |
Selling & General & Admin | 5.82M | 3.97M | 3.21M | 2.53M | 2.11M | 2M | 2.57M | 2.06M | 1.85M | 1.49M | 1.7M | 1.78M | 1.6M | 1.39M | 939K | 286K | 281K |
Research & Development | 2.17M | 5.29M | 3.04M | 4.87M | 6.81M | 4.23M | 3.37M | 2.27M | 3.03M | 3.84M | 4.8M | 1.86M | 1.93M | 1.36M | 3.78M | 493K | 450K |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 7.99M | 9.26M | 6.25M | 7.4M | 8.92M | 6.23M | 5.94M | 4.32M | 4.88M | 5.33M | 6.5M | 3.64M | 3.54M | 2.75M | 4.71M | 779K | 731K |
Interest Expense | 15K | 20K | 15K | 16K | 20K | 19K | 18K | 32K | 12K | 3K | 3K | n/a | n/a | n/a | 55K | 321K | 252K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | -284K | -82K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | n/a | 9.26M | 6.25M | 7.4M | 9.2M | 6.31M | 5.94M | 4.32M | 4.88M | 5.33M | 6.5M | 3.64M | 3.54M | 2.75M | 4.71M | 779K | 731K |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | -79K | 32K | 10.58M | 3K | 3K | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 116.82M | 66.99M | 8.89M | 3.79M | 15.23M | 3.48M | 3.26M | 1.52M | 1.52M | 1.52M | 1.51M | 1.5M | 1.5M | 1.42M | 1.42M | 1.4M | 1.42M |
Shares Outstanding (Diluted) | 123.83M | 66.99M | 8.89M | 9.41M | 15.23M | 3.48M | 3.26M | 1.52M | 1.52M | 1.52M | 1.51M | 1.5M | 1.5M | 1.42M | 1.42M | 1.4M | 1.42M |
EPS (Basic) | -0.05 | -0.03 | -0.05 | 0.08 | -0.6 | -0.22 | -0.13 | -0.25 | -1.65 | -0.35 | -0.37 | -0.24 | -0.24 | -0.19 | -0.37 | -0.08 | -0.07 |
EPS (Diluted) | -0.05 | -0.03 | -0.05 | -0.15 | -0.6 | -0.22 | -0.13 | -0.25 | -1.65 | -0.35 | -0.37 | -0.24 | -0.24 | -0.19 | -0.37 | -0.08 | -0.07 |
EBITDA | -7.99M | -21.37M | -3.96M | -7.4M | -20.66M | -7.7M | -4.24M | -3.73M | -14.52M | -5.32M | -5.55M | -3.63M | -3.54M | -2.75M | -4.71M | -779K | n/a |
EBIT | n/a | -21.5M | -4.08M | 9.87M | -20.94M | -7.78M | -4.32M | -3.81M | -14.56M | -5.33M | -5.55M | -3.64M | -3.54M | -2.75M | -5.15M | -779K | -712K |
Depreciation & Amortization | n/a | 134K | 123K | -113K | 284K | 82K | 79K | 78K | 45K | 2K | 1K | 2K | 2K | 1K | 4.71M | 779K | 731K |